BRPI0415887A - remoção de agregados de elevado peso molecular usando cromatografia de hidroxiapatita - Google Patents

remoção de agregados de elevado peso molecular usando cromatografia de hidroxiapatita

Info

Publication number
BRPI0415887A
BRPI0415887A BRPI0415887-3A BRPI0415887A BRPI0415887A BR PI0415887 A BRPI0415887 A BR PI0415887A BR PI0415887 A BRPI0415887 A BR PI0415887A BR PI0415887 A BRPI0415887 A BR PI0415887A
Authority
BR
Brazil
Prior art keywords
molecular weight
high molecular
removal
weight aggregates
hydroxyapatite chromatography
Prior art date
Application number
BRPI0415887-3A
Other languages
English (en)
Inventor
Shujun Sun
Christopher Gallo
Brian Kelley
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Priority to BR122020007658-5A priority Critical patent/BR122020007658B1/pt
Publication of BRPI0415887A publication Critical patent/BRPI0415887A/pt
Publication of BRPI0415887B1 publication Critical patent/BRPI0415887B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3847—Multimodal interactions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B01J20/04—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium
    • B01J20/048—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium containing phosphorus, e.g. phosphates, apatites, hydroxyapatites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/282—Porous sorbents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

"REMOçãO DE AGREGADOS DE ELEVADO PESO MOLECULAR USANDO CROMATOGRAFIA DE HIDROXIAPATITA". Esta invenção refere-se à aplicação de cromatografia de hidroxiapatita à purificação de pelo menos um anticorpo a partir de uma preparação contendo agregados de elevado peso molecular. Além disso, esta invenção refere-se a uma integração de cromatografia de hidroxiapatita cerâmica em um protocolo cromatográfico de combinação para a remoção de agregados de elevado peso molecular a partir de uma preparação de anticorpos.
BRPI0415887-3A 2003-10-27 2004-10-06 métodos para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita BRPI0415887B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122020007658-5A BR122020007658B1 (pt) 2003-10-27 2004-10-06 Método para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US51401803P 2003-10-27 2003-10-27
US60/514,018 2003-10-27
US52333503P 2003-11-20 2003-11-20
US60/523,335 2003-11-20
PCT/US2004/032883 WO2005044856A2 (en) 2003-10-27 2004-10-06 Removal of high molecular weight aggregates using hydroxyapatite chromatography

Publications (2)

Publication Number Publication Date
BRPI0415887A true BRPI0415887A (pt) 2007-01-09
BRPI0415887B1 BRPI0415887B1 (pt) 2021-01-26

Family

ID=34576743

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122020007658-5A BR122020007658B1 (pt) 2003-10-27 2004-10-06 Método para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita
BRPI0415887-3A BRPI0415887B1 (pt) 2003-10-27 2004-10-06 métodos para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122020007658-5A BR122020007658B1 (pt) 2003-10-27 2004-10-06 Método para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita

Country Status (19)

Country Link
US (2) US9469672B2 (pt)
EP (2) EP2336172B1 (pt)
JP (2) JP5004586B2 (pt)
KR (2) KR101221862B1 (pt)
CN (2) CN1898266B (pt)
AU (1) AU2004286938B2 (pt)
BR (2) BR122020007658B1 (pt)
CA (1) CA2543193C (pt)
CO (1) CO5690649A2 (pt)
DK (2) DK2336172T3 (pt)
EC (1) ECSP066583A (pt)
ES (2) ES2530446T3 (pt)
IL (1) IL175229A (pt)
MX (1) MXPA06004472A (pt)
NZ (1) NZ547315A (pt)
PL (2) PL1678208T3 (pt)
PT (2) PT1678208E (pt)
RU (2) RU2409591C2 (pt)
WO (1) WO2005044856A2 (pt)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
EP2336172B1 (en) * 2003-10-27 2014-12-10 Wyeth LLC Removal of high molecular weight aggregates using hydroxyapatite chromatography
AU2006223180B2 (en) * 2005-03-11 2011-11-24 Wyeth Llc A method of weak partitioning chromatography
TWI372763B (en) * 2005-06-17 2012-09-21 Wyeth Llc Methods of purifying anti a beta antibodies
EP1893647A2 (en) * 2005-06-23 2008-03-05 MedImmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
AR058140A1 (es) * 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
BRPI0620316A2 (pt) * 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
EP2012118A4 (en) 2006-04-25 2009-12-16 Tosoh Corp ISOLENT FOR IGG PURIFICATION AND METHOD FOR PURIFYING AN IGG MONOMER THEREFOR
US20100234577A1 (en) * 2006-06-14 2010-09-16 Smithkline Beecham Corporation Methods for purifying antibodies using ceramic hydroxyapatite
DK2061803T4 (da) 2006-08-28 2022-12-05 Ares Trading Sa Fremgangsmåde til oprensning af fc-holdige proteiner
EA017733B1 (ru) * 2006-08-28 2013-02-28 Арес Трейдинг С.А. СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ
WO2008031020A2 (en) * 2006-09-08 2008-03-13 Wyeth Arginine wash in protein purification using affinity chromatography
TWI456062B (zh) 2006-09-13 2014-10-11 Abbvie Inc 細胞培養改良
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
US7999085B2 (en) * 2007-01-09 2011-08-16 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of protein by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
CA2674213A1 (en) * 2007-01-26 2008-07-31 Merck Serono S.A. Purification of fc-taci fusion proteins using the oilbody technology
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
CA2703086C (en) * 2007-10-26 2014-11-25 Asahi Kasei Chemicals Corporation Method for purifying protein
US8188242B2 (en) 2008-04-08 2012-05-29 Bio-Rad Laboratories, Inc. Chromatography purification of antibodies
MX2011001506A (es) † 2008-08-14 2011-03-15 Genentech Inc Metodos para eliminar un contaminante utilizado cromatografia de membrana de intercambio de ion en desplazamiento de proteina indigena.
MX2011004201A (es) 2008-10-20 2011-05-24 Abbott Lab Desactivacion viral durante purificacion de anticuerpos.
AU2009347206C1 (en) 2008-10-20 2016-12-08 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
BRPI0919879A2 (pt) * 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
EP2362767B1 (en) 2008-10-29 2017-12-06 Ablynx N.V. Formulations of single domain antigen binding molecules
EP2350130B1 (en) * 2008-10-31 2018-10-03 Wyeth LLC Purification of acidic proteins using ceramic hydroxyapatite chromatography
CN102395597A (zh) * 2009-03-11 2012-03-28 惠氏有限责任公司 纯化小模块免疫药物蛋白的方法
US8481694B2 (en) 2009-04-29 2013-07-09 Bio-Rad Laboratories, Inc. Purification of immunoconjugates
JPWO2011001963A1 (ja) 2009-07-03 2012-12-13 旭化成ケミカルズ株式会社 多孔質基材に固定されたグラフト鎖に結合しているアミノ基及びアルキル基を有する多孔膜を用いた抗体の精製方法
ES2813398T3 (es) 2009-10-20 2021-03-23 Abbvie Inc Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A
EP2513134B1 (en) 2009-12-18 2017-09-06 Novartis AG Wash solution and method for affinity chromatography
WO2011090720A2 (en) * 2009-12-29 2011-07-28 Dr. Reddy's Laboratories Ltd Purification of proteins
WO2011088225A1 (en) 2010-01-15 2011-07-21 Bio-Rad Laboratories, Inc. Surface neutralization of apatite
RU2012146448A (ru) 2010-04-14 2014-05-20 Ф.Хоффманн-Ля Рош Аг Удаление агрегатов иммуноглобулинов
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
WO2011156073A1 (en) * 2010-06-08 2011-12-15 Millipore Corporation Removal of protein aggregates from biopharmaceutical preparations using calcium phosphate salts
US8895707B2 (en) * 2010-08-18 2014-11-25 Bio-Rad Laboratories, Inc. Elution of proteins from hydroxyapatite resins without resin deterioration
CA2814781A1 (en) 2010-11-01 2012-05-10 Diderik Reinder Kremer Single unit ion exchange chromatography antibody purification
JP5881744B2 (ja) * 2011-02-02 2016-03-09 バイオ−ラッド ラボラトリーズ インコーポレーティッド アルカリ溶液でのアパタイトの表面中和方法
SG195306A1 (en) * 2011-06-08 2013-12-30 Agency Science Tech & Res Purification of biological products by constrained cohydration chromatography
US20140187749A1 (en) 2011-06-16 2014-07-03 Dsm Ip Assets B.V. Single unit chromatography antibody purification
SG10201701224UA (en) * 2012-03-12 2017-04-27 Merck Patent Gmbh Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode
US9815695B2 (en) 2012-05-30 2017-11-14 Bio-Rad Laboratories, Inc. In situ restoration of apatite-based chromatography resins
WO2014003142A1 (ja) * 2012-06-27 2014-01-03 旭化成メディカル株式会社 抗体
JP2014105180A (ja) * 2012-11-27 2014-06-09 Hoya Corp モノマー化方法
SG10201707477SA (en) 2013-03-13 2017-10-30 Eleven Biotherapeutics Inc Chimeric cytokine formulations for ocular delivery
CA2909969A1 (en) * 2013-05-13 2014-12-31 Medimmune, Llc Separation of recombinant polyclonal antibody multimers with minimal separation of monomers
MX384222B (es) 2013-07-05 2025-03-14 Lab Francais Du Fractionnement Matriz de cromatografia de afinidad.
WO2015005960A1 (en) 2013-07-12 2015-01-15 Emd Millipore Corporation Removal of fragments from a sample containing a target protein using activated carbon
JP6479305B2 (ja) * 2013-07-12 2019-03-06 株式会社Ｕｍｎファーマ ウイルス様粒子の精製方法
WO2015088677A1 (en) 2013-12-12 2015-06-18 Emd Millipore Corporation Protein separations using an acrylamide containing filter
BR112016014824A2 (pt) * 2013-12-27 2017-09-19 Chugai Pharmaceutical Co Ltd Método para purificar anticorpo que tem ponto isoelétrico baixo
CN105392569B (zh) * 2014-06-23 2019-08-20 生物辐射实验室股份有限公司 磷灰石预处理
US10099157B2 (en) 2014-06-23 2018-10-16 Bio-Rad Laboratories, Inc. Apatite in-situ restoration
EP3233230B1 (en) 2014-12-15 2024-06-12 Merck Patent GmbH Target molecule capture from crude solutions
KR102490956B1 (ko) 2015-03-13 2023-01-19 브리스톨-마이어스 스큅 컴퍼니 불순물을 제거하기 위한 크로마토그래피 동안의 알칼리성 세척의 용도
US11661438B2 (en) 2015-12-21 2023-05-30 Pfizer, Inc. Purification of antibody drug conjugates using a sodium phosphate gradient
US11919924B1 (en) * 2016-03-15 2024-03-05 Fresenius Kabi Deutschland Gmbh Methods of purifying and producing an adalimumab antibody
US11186858B1 (en) 2016-03-15 2021-11-30 Fresenius Kabi Deutschland Gmbh Methods for increasing biosimilarity
CN106977591B (zh) * 2017-05-04 2020-05-05 广州康盛生物科技股份有限公司 一种分离纯化重组葡萄球菌蛋白a的方法
WO2019040671A1 (en) * 2017-08-22 2019-02-28 Biogen Ma Inc. METHODS OF PURIFYING ANTIBODIES HAVING REDUCED AGGREGATES OF HIGH MOLECULAR WEIGHT
WO2019116096A1 (en) * 2017-12-15 2019-06-20 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Production of fc fragments
MX2020008931A (es) * 2018-02-27 2020-10-01 Pfizer Purificacion de anticuerpos.
CN111902720B (zh) * 2018-03-21 2025-02-07 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
JP2021519339A (ja) 2018-04-03 2021-08-10 メルク パテント ゲーエムベーハー Ｃｅｘクロマトグラフィー媒体及び生物製剤供給原料からの標的タンパク質の低塩溶出
WO2019224660A1 (ja) * 2018-05-24 2019-11-28 ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 吸着剤の生産方法
JP6704074B2 (ja) * 2019-02-04 2020-06-03 株式会社Ｕｍｎファーマ ウイルス様粒子の精製方法
IL293047A (en) 2019-11-22 2022-07-01 Morphosys Ag A method for increasing antibody yield during ion exchange chromatography
JP2020099909A (ja) * 2020-03-17 2020-07-02 ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 処理方法、生産方法およびハイドロキシアパタイト充填剤
IL296767A (en) 2020-03-30 2022-11-01 Ablynx Nv A method for the production and purification of single variable multivalent immunoglobulin sites
EP4142792A4 (en) * 2020-05-01 2024-11-27 Kashiv Biosciences, LLC An improved process of purification of protein

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US428894A (en) 1890-05-27 Process of making tool-handles
US523335A (en) 1894-07-24 Air-bolt for flour-mills
US514018A (en) 1894-02-06 Edward j
US419964A (en) 1890-01-21 Transom-lifter
US4745183A (en) * 1984-02-21 1988-05-17 Bio-Rad Laboratories, Inc. Use of hydroxylapatite for the analysis and preparation of purified monoclonal antibodies
JPH03291300A (ja) * 1989-12-28 1991-12-20 Mitsui Toatsu Chem Inc ポリクローナル抗体の分離方法
GB9022545D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Culture medium
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
WO2003059935A2 (en) 2001-12-21 2003-07-24 Immunex Corporation Methods for purifying protein
AU2004215653B2 (en) 2003-02-28 2011-03-17 Lonza Biologics Plc. Antibody purification by protein A and ion exchange chromatography
EP2336172B1 (en) * 2003-10-27 2014-12-10 Wyeth LLC Removal of high molecular weight aggregates using hydroxyapatite chromatography

Also Published As

Publication number Publication date
US20050107594A1 (en) 2005-05-19
JP5490156B2 (ja) 2014-05-14
CO5690649A2 (es) 2006-10-31
EP2336172B1 (en) 2014-12-10
RU2573910C2 (ru) 2016-01-27
AU2004286938A1 (en) 2005-05-19
RU2010139827A (ru) 2012-03-27
CA2543193A1 (en) 2005-05-19
EP1678208B1 (en) 2013-05-15
EP1678208A2 (en) 2006-07-12
PT2336172E (pt) 2015-02-20
PL2336172T3 (pl) 2015-04-30
WO2005044856A3 (en) 2005-06-23
CN1898266B (zh) 2011-09-21
PL1678208T3 (pl) 2013-09-30
DK2336172T3 (en) 2015-01-26
MXPA06004472A (es) 2006-06-20
BRPI0415887B1 (pt) 2021-01-26
CN1898266A (zh) 2007-01-17
JP5004586B2 (ja) 2012-08-22
WO2005044856A2 (en) 2005-05-19
ES2530446T3 (es) 2015-03-02
ECSP066583A (es) 2006-10-17
IL175229A (en) 2013-08-29
CN102276717A (zh) 2011-12-14
CA2543193C (en) 2015-08-11
RU2006113695A (ru) 2007-12-10
US20130197198A1 (en) 2013-08-01
KR20060120163A (ko) 2006-11-24
KR20120003027A (ko) 2012-01-09
ES2418830T3 (es) 2013-08-16
KR101321876B1 (ko) 2013-10-28
EP2336172A1 (en) 2011-06-22
NZ547315A (pt) 2008-07-31
KR101221862B1 (ko) 2013-01-14
IL175229A0 (en) 2006-09-05
BR122020007658B1 (pt) 2021-07-27
US9469672B2 (en) 2016-10-18
PT1678208E (pt) 2013-07-10
JP2007532477A (ja) 2007-11-15
RU2409591C2 (ru) 2011-01-20
AU2004286938B2 (en) 2011-06-30
DK1678208T3 (da) 2013-07-08
CN102276717B (zh) 2015-09-09
US9822143B2 (en) 2017-11-21
JP2012111769A (ja) 2012-06-14

Similar Documents

Publication Publication Date Title
BRPI0415887A (pt) remoção de agregados de elevado peso molecular usando cromatografia de hidroxiapatita
SE0101675D0 (sv) Novel composition
DK1379239T3 (da) N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren
DE60131967D1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
AR048912A1 (es) Inmunoglobulinas anti-nogo
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
MXPA03010062A (es) Funcionalidad i de la proteina de canola aislada.
CL2003001814A1 (es) Compuestos derivados de 1,3,8-triazaespiro[4,5]decan-4-ona jidroxialquil sustituidos, moduladores del receptor orl-1; compuestos intermediarios; composicion farmaceutica que contiene dichos compuestos; procedimiento de preparacion de la composicion f
BR0308261A (pt) Métodos extrativos para puruficação de sucralose
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
BRPI0608584B8 (pt) métodos de recuperar um produto purificado
CY1109088T1 (el) Μεθοδος για την παρασκευη υποκατεστημενων ενωσεων 3-αρυλο-βουτυλ-αμινης
BR0213207A (pt) remodelagem e glicoconjugação de peptìdeos
HRP20070196T3 (hr) Postupak za pročišćavanje il-18 vezivnog proteina
HN1998000157A (es) Agonistas de prostaglandinas
CY1106468T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
BRPI0517973A (pt) método para purificar o fsh
BR0207640A (pt) Composição farmacêutica oral de cefpodoxima proxetil
ATE479655T1 (de) Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
BRPI0414634A (pt) agonistas de receptor b2, adrenérgico de etilamino amino-substituìdo
EP1423137A4 (en) Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
DK1385826T3 (da) Fremgangsmåde til fremstilling af (S)-(+)- og (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azapin-5-carboxamid
UY27852A1 (es) Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
TWI256304B (en) Pharmaceutical compositions based on azetidine derivatives

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2848 DE 05-08-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.